Gallic acid functionalized UiO-66 for the recovery of ribosylated metabolites from human urine samples

Early diagnosis of disease biomarkers has been focused in recent years through Omics sciences. Nucleosides are the biomarkers of cancers including lung cancer, colorectal cancer, thyroid cancer, bladder cancer, cervical cancer and breast cancer. Nucleosides are directly excreted in the urine of diseased states whereas they are decomposed into other forms as modified nucleosides in healthy conditions. A dual affinity probe (gallic acid modified UiO-66) is prepared and reported for the first time in selectively enriching the ribosylated metabolites and modified nucleosides. Material is characterized by SEM, EDX, FTIR and Nitrogen adsorption porosimetry. The enrichment is benefitted from the interaction ability of zirconium towards glycosylated molecules, rich surface chemistry (3 terminal hydroxyl groups) on gallic acid and high surface area (384 m(2)/g) of 3-dimensional porous structure of metal organic frameworks (MOFs). Material shows selectivity of 1:500, recovery up to 137.1% and binding capacity of 2340.9 mu g/g. Forty-three (43) nucleosides are enriched from human urine samples and 12 potential nucleoside biomarkers from colorectal cancer samples are quantified and their concentration is found higher than in the healthy controls.